Calcium activated phospholipid scrambling

Across TCGA cell cohorts, RNA activity of the Calcium activated phospholipid scrambling pathway is significantly associated with the drug response of multiple features, with the BLOOD_Lymphoma cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Gefitinib, YK-4-279, and Dabrafenib, each associated with the pathway in up to 5 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Gefitinib grouped by Calcium activated phospholipid scrambling-low versus -high activity in BLOOD_Lymphoma.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BLOOD_Lymphoma	Gefitinib →	-0.883	-0.422	.049	.025	3	4
UPPER_AERODIGESTIVE_TRACT	YK-4-279 →	-0.839	-0.422	.015	.023	3	4
SKIN	Dabrafenib →	+2.174	+0.393	.020	.014	2	4
BLOOD_Lymphoma	Rucaparib →	-0.739	-0.422	.023	.025	3	3
BLOOD_Lymphoma	MCT4_1422 →	-0.485	-0.448	.003	.007	3	3
BLOOD_Lymphoma	Dactinomycin →	-0.656	-0.422	.022	.025	3	3

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Gefitinib by Calcium activated phospholipid scrambling activity — BLOOD_Lymphoma

Explore this box plot interactively →